BREAKING: Futures Rise After S&P 500, Nasdaq Hit Fresh Highs In a welcome move, Cardinal Health (CAH) stock saw its Relative Strength Rating rise from 70 to 74 on Wednesday. Â Can You Really Time The Stock Market? IBD's unique RS Rating measures technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database. Decades of… Related news Cardinal Health Stock Scores Relative Strength Rating Upgrade 9/28/2025Cardinal Health shows ris ...

The planned 230,000 square-foot plant is the healthcare company's latest step in a 10-year plan to modernize and expand its distribution network. ...

Core Insights - Cardinal Health announced plans for a new flagship forward distribution center in Indianapolis, Indiana, aimed at expanding and modernizing its national pharmaceutical distribution network [1][2] - The facility will be 230,000 square feet and will feature an industry-first robotic storage and retrieval system, enhancing operational efficiency and service reliability [2][3] - The center is expected to be fully operational by fall 2027 and will create over 100 new jobs in Indiana [4] Investment and Strategy - The company is making strategic investments in its core distribution network to enhance efficiency and meet evolving customer needs [2] - Automation is a key component of Cardinal Health's strategy, aimed at improving productivity, customer service, and employee safety [3] Technological Advancements - The new distribution center will utilize advanced automation technology for real-time inventory visibility and intelligent order fulfillment [2][3] - The facility's design and implementation are in partnership with Swisslog, a leader in warehouse automation [2] Employment Impact - The establishment of the Indianapolis distribution center will create more than 100 new jobs, reinforcing Indiana's role as a strategic transit hub for the company [4]

Group 1 - Cardinal Health (CAH) stock received a Relative Strength (RS) Rating upgrade from 66 to 71, indicating an improvement in share price performance but still below the desired threshold of 80 [1] - Cencora has shown improved technical performance with a Relative Strength Rating upgrade, reaching a score of 86, although it remains shy of key thresholds [3] - Cencora reported $81.5 billion in sales last quarter, marking a significant performance in a challenging market environment [3] Group 2 - The market is currently influenced by tariff wars, which have led to sellers dominating the trading environment [3] - Cencora has been recognized as a new addition to the Big Cap 20, reflecting its rising prominence in the market [3] - The stock lists from Investor's Business Daily (IBD) include notable names such as Mueller Water and Netflix, indicating a diverse range of investment opportunities [3]

Cardinal Health (CAH) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earnin ...

Company Overview - Cardinal Health is one of the world's largest healthcare services and products providers, operating across various segments including Pharmaceutical & Specialty Solutions and Global Medical Products & Distribution [12] - The company serves nearly 90% of U.S. hospitals and delivers over 43,000 pharmaceutical shipments daily [12] - Cardinal Health manages a broad portfolio of medical, surgical, and laboratory products, and operates nearly 130 nuclear pharmacies and 30 PET cyclotron facilities [12] Investment Ratings - Cardinal Health has a Zacks Rank of 2 (Buy) and a VGM Score of A, indicating strong potential for growth [13][14] - The company is particularly appealing for growth investors, with a Growth Style Score of A and a forecasted year-over-year earnings growth of 14.2% for the current fiscal year [13] Earnings Estimates - Seven analysts have revised their earnings estimates upwards in the last 60 days for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.20 to $9.41 per share [13] - Cardinal Health boasts an average earnings surprise of +9.2%, further indicating its strong performance potential [13]

Group 1: Stock Performance - Cardinal Health's stock closed at $148.96, reflecting a -3.64% change from the previous day's closing price, underperforming the S&P 500's daily loss of 0.5% [1] - Over the past month, Cardinal Health's shares have appreciated by 3.58%, outperforming the Medical sector's loss of 0.7% and the S&P 500's gain of 2.74% [1] Group 2: Upcoming Earnings Disclosure - Cardinal Health is set to release its earnings report on October 30, 2025, with an expected EPS of $2.22, representing an 18.09% increase from the prior-year quarter [2] - The Zacks Consensus Estimate projects net sales of $59.05 billion, up 12.96% from the year-ago period [2] Group 3: Annual Estimates - For the annual period, the Zacks Consensus Estimates anticipate earnings of $9.41 per share and revenue of $249.31 billion, indicating increases of +14.2% and +12.01%, respectively, from the last year [3] - Recent changes to analyst estimates reflect shifting dynamics in short-term business patterns, with positive revisions indicating analysts' confidence in business performance and profit potential [3] Group 4: Valuation Metrics - Cardinal Health is currently trading at a Forward P/E ratio of 16.42, which is higher than the industry average Forward P/E of 14.68, suggesting a premium valuation [6] - The company has a PEG ratio of 1.31, compared to the Medical - Dental Supplies industry average PEG ratio of 1.65 [7] Group 5: Industry Ranking - The Medical - Dental Supplies industry has a Zacks Industry Rank of 169, placing it in the bottom 32% of all 250+ industries [7] - The Zacks Industry Rank measures the strength of industry groups by evaluating the average Zacks Rank of individual stocks within those groups [8]

Group 1 - Cardinal Health, Inc. (NYSE:CAH) is recognized as one of the 11 cheap quarterly dividend stocks to buy currently [1] - The company is a significant distributor of branded and generic drugs, medical supplies, and laboratory products, serving over 90% of hospitals in the US and operating in more than 30 countries [2] - Cardinal Health has a strong dividend history, having raised its payout for 39 consecutive years, with a payout ratio of about 25% of this year's expected earnings, indicating potential for further increases [3] Group 2 - The current quarterly dividend offered by Cardinal Health is $0.5107 per share, resulting in a dividend yield of 1.32% as of September 23 [4] - Analysts project an earnings growth of nearly 11% annually over the next three to five years, which could support continued dividend expansion [3]

PresentationAllen LutzBofA Securities, Research Division All right. Good morning, everyone. Thank you for attending. My name is Allen Lutz, health care tech and distribution analyst here at Bank of America. We are ecstatic to have the Cardinal Health management team here. We have Jason Hollar, CEO; Aaron Alt, CFO; and Head of Investor Relations, Matt Sims. I think, Matt, you had a couple of comments before we get started. ...

Summary of Cardinal Health 2025 Conference Call Company Overview - **Company**: Cardinal Health (NYSE: CAH) - **Industry**: Healthcare Supply Chain - Cardinal Health operates across the entire U.S. healthcare supply chain, connecting innovators, manufacturers, and patients, with a significant focus on pharmaceutical and specialty solutions, which account for over $200 billion of the total $220 billion in revenue [4][6]. Core Business Segments - **Pharmaceutical and Specialty Solutions**: The cornerstone of Cardinal Health's operations, contributing significantly to revenue and profitability [4][5]. - **Growth Businesses**: Includes Nuclear & Precision Health Solutions, At-Home Solutions, and OptiFreight® Logistics, which are positioned for growth due to unique market trends [5][6]. - **Global Medical Products and Distribution (GMPD)**: A turnaround business that has improved profitability after previous losses due to inflation and tariffs [6][10]. Financial Performance and Guidance - Cardinal Health achieved an 18% growth in earnings per share (EPS), exceeding the previously projected 12% to 14% growth [9][14]. - Long-term growth plans include generating adjusted free cash flow of at least $10 billion and maintaining a solid balance sheet with a BBB rating [18][19]. - The company plans to return $750 million to shareholders and maintain a growing dividend, emphasizing its status as a dividend aristocrat [18][19]. Strategic Initiatives - **Investor Day Takeaways**: Focus on accountability, performance measurement, and strategic evolution across five operating segments [8][10]. - **Investment in Technology**: Cardinal Health is investing in automation and technology to enhance operational efficiency, including refreshing distribution centers [12][46]. - **Acquisitions**: Recent acquisitions, such as Solaris in the urology space, are aimed at expanding capabilities and driving growth in specialty services [15][30]. Market Trends and Demand - Strong demand in the pharmaceutical and specialty solutions business is driven by procedures and scripts, with expectations of continued growth despite potential normalization in industry growth trends [21][20]. - The company anticipates a slight headwind from COVID vaccine contributions compared to previous years, but overall demand remains strong [27][29]. Management Services Organization (MSO) Strategy - Cardinal Health is focusing on acquiring practices in fragmented markets like autoimmune and urology, with a goal to create scale and provide comprehensive services to physicians [30][35]. - The MSO strategy aims to consolidate independent practices, providing them with back-office support and technology to enhance operational efficiency [31][40]. Challenges and Risks - Potential impacts from drug pricing policies and tariffs are acknowledged, but Cardinal Health believes it is well-positioned to manage these risks due to its diverse revenue streams and operational model [43][49]. - The company is cautious about the evolving landscape of generics, with expectations of increased contributions from generics over the next few years due to higher loss of exclusivity (LOE) [51][54]. Conclusion - Cardinal Health is strategically positioned for growth with a focus on its core pharmaceutical and specialty solutions business, while also expanding its presence in high-growth areas through acquisitions and investments in technology. The company remains committed to delivering value to shareholders while navigating industry challenges and market dynamics.